Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
乾癬性関節炎患者における3年間のウステキヌマブまたはTNF阻害薬の患者報告アウトカムと労働生産性の改善: PsABio 実臨床結果
Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y
Results from the 3-year PsABio study demonstrated that, generally, ustekinumab and TNFi treatment led to an improvement in PROs. In coming to this conclusion, researchers aimed to evaluate the real-world effect of ustekinumab or a TNFi on PRO and their association with effectiveness endpoints in PsA patients over 3 years.
ウステキヌマブまたはTNF阻害薬で治療した乾癬性関節炎患者における性差: 実臨床データ
Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead089
These real-world data from PsABio on gender differences suggest that, at the start of biologic treatment, females have a worse clinical picture of PsA than males. In coming to these conclusions and others, this study sought to investigate effects of gender on disease characteristics and treatment impact in patients with PsA.
Keywords:
乾癬性関節炎患者におけるIL-12/23 経路阻害薬であるustekinumabとTNF阻害薬の継続率と有効性: 実臨床コホートPsABIOレジストリの1年結果
Ann Rheum Dis 2022 doi: 10.1136/annrheumdis-2021-221640
Many RCTs have demonstrated efficacy and safety of biologics in PsA. However, long term comparative real world data is lacking. This study aimed to evaluate the real-world effectiveness and persistence of the IL-12/23 inhibitor ustekinumab or a TNFi for PsA 1 year post initiation. As a result, they found that PS-adjusted comparisons demonstrated comparable overall persistence, effectiveness and safety for both modes of action in PsA.